CH672987A5 - - Google Patents

Download PDF

Info

Publication number
CH672987A5
CH672987A5 CH2611/87A CH261187A CH672987A5 CH 672987 A5 CH672987 A5 CH 672987A5 CH 2611/87 A CH2611/87 A CH 2611/87A CH 261187 A CH261187 A CH 261187A CH 672987 A5 CH672987 A5 CH 672987A5
Authority
CH
Switzerland
Prior art keywords
bromocriptine
disease
therapy
day
test
Prior art date
Application number
CH2611/87A
Other languages
German (de)
English (en)
Inventor
Douglas Dr Larson
Peter Hiestand
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of CH672987A5 publication Critical patent/CH672987A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CH2611/87A 1986-07-14 1987-07-09 CH672987A5 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88511086A 1986-07-14 1986-07-14

Publications (1)

Publication Number Publication Date
CH672987A5 true CH672987A5 (da) 1990-01-31

Family

ID=25386156

Family Applications (1)

Application Number Title Priority Date Filing Date
CH2611/87A CH672987A5 (da) 1986-07-14 1987-07-09

Country Status (13)

Country Link
JP (1) JPS6323817A (da)
KR (1) KR880001292A (da)
AU (1) AU602154B2 (da)
CH (1) CH672987A5 (da)
DE (1) DE3722383A1 (da)
DK (1) DK363887A (da)
FR (1) FR2601245A1 (da)
GB (1) GB2192541B (da)
IT (1) IT1224222B (da)
NL (1) NL8701631A (da)
PH (1) PH24525A (da)
SE (1) SE8702843L (da)
ZA (1) ZA875145B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814521A1 (de) * 1987-05-07 1988-11-17 Sandoz Ag Neue anwendung von dopaminrezeptor-agonisten
EP0327040A3 (de) * 1988-02-05 1990-11-28 Predrag Dr.Sc. Sikiric Verwendung von Dopamin und/oder von Dopamin-Agonisten zur Herstellung eines Arzneimittels für die Behandlung des Verdauungstrakts
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5830895A (en) * 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5716932A (en) * 1988-05-10 1998-02-10 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
RU2104698C1 (ru) * 1991-12-23 1998-02-20 Дзе Борд оф Сьюпервайзорз оф Луизиана Стейт Юниверсити энд Эгрикалчурал энд Мекэникал Колледж Способ лечения патологических отклонений при диабете типа ii
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US5626860A (en) * 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
ES2425581T3 (es) 2006-11-23 2013-10-16 Sinoxa Pharma Gmbh Composiciones farmacéuticas para el tratamiento de la arteriopatía capilar
CN109689057A (zh) * 2016-04-20 2019-04-26 维罗技术有限责任公司 用于治疗代谢失调的组合物和方法
US11510921B2 (en) 2017-10-18 2022-11-29 Veroscience Llc Bromocriptine formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.

Also Published As

Publication number Publication date
GB8716323D0 (en) 1987-08-19
IT1224222B (it) 1990-09-26
GB2192541B (en) 1990-05-02
SE8702843L (sv) 1988-01-15
DE3722383A1 (de) 1988-01-28
NL8701631A (nl) 1988-02-01
IT8748160A0 (it) 1987-07-10
KR880001292A (ko) 1988-04-22
AU602154B2 (en) 1990-10-04
SE8702843D0 (sv) 1987-07-13
GB2192541A (en) 1988-01-20
DK363887D0 (da) 1987-07-13
AU7558787A (en) 1988-01-21
DK363887A (da) 1988-01-15
ZA875145B (en) 1989-02-22
JPS6323817A (ja) 1988-02-01
PH24525A (en) 1990-07-18
FR2601245A1 (fr) 1988-01-15

Similar Documents

Publication Publication Date Title
CH672987A5 (da)
DE3247062C2 (da)
DE3526545A1 (de) Neue pharmazeutische anwendung von (nva)(pfeil hoch)2(pfeil hoch)- und dihydro-(val)(pfeil hoch)2(pfeil hoch)-cyclosporin
DE3338995A1 (de) Bilobalid enthaltende arzneimittel
DE69925488T2 (de) Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen
DE69634092T2 (de) Herstellung von antikörpern
WO1990014829A1 (de) Lysolecithinderivate zur behandlung von autoimmunerkrankungen
EP1600164A2 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE3390419T1 (de) Arzneimittel zur Behandlung der Ulkuskrankheit
EP0236390B1 (de) Mittel gegen multiple sklerose
WO2002038150A1 (de) Aktivatoren von peroxisom-proliferator-aktivierten rezeptoren alpha, beta als arzneimittel zur behandlung von immunologisch bedingten hautstörungen
DE4136215A1 (de) Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
DE3916417C2 (da)
DE3715218A1 (de) Arzneimittel zur stimulation des lernens und zur verbesserung des gedaechtnisses
Kennedy et al. Spinal changes in the neuropathy of thallium poisoning: a case with neuropathological studies
DE60206280T2 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
WO2003043648A2 (de) Sfcyr iib oder sfcyr iii für die behandlung von autoimmunkrankheiten
DE2660486C2 (de) Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel
DE1902865A1 (de) Substituierte Insulin-Derivate,Verfahren zu ihrer Herstellung und ihre Verwendung in pharmazeutischen Zubereitungen
DE60020580T2 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten, die mittel, welche icam-1/lfa-1 interaktionen inhibieren und mittel, welche cd40-cd40-ligande interaktionen inhibieren, enthalten
DE69937057T2 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
DE4435525C2 (de) Präparat zur Behandlung von Entmarkungsenzephalitiden
DE3142590A1 (de) Verwendung von biotin zur behandlung der zuckerkrankheit
DE19636252C2 (de) Pharmazeutisches Kombinationspräparat zur Behandlung von rheumatischen Erkrankungen
WO1991008746A1 (de) Eliminierung von aktivierten lymphozyten

Legal Events

Date Code Title Description
PL Patent ceased